Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR
The presence of neuronal elements that are indicative of dopaminergic neurotransmission in cerebellum suggest that this brain region may contribute to the motor symptoms or dyskinesia seen in Parkinson's disease. Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of markers for dopaminergic neurotransmission in the cerebellum from postmortem brain tissue obtained from normal subjects and patients dying with Parkinson's disease who were receiving treatment with dopaminergic drugs. Dopamine D1-3 receptors, tyrosine hydroxylase and dopamine transporter mRNA was detected in the uvula and nodulus (lobules 9 and 10, respectively) of the vermis of cerebellum from normal individuals. In Parkinson's disease, the level of dopamine D1 and D3 receptor mRNA was significantly reduced in lobule 9 and the level of tyrosine hydroxylase mRNA was significantly reduced in lobule 10. No alteration in the level of dopamine D2 receptor or dopamine transporter mRNA was found in either lobule in patients with Parkinson's disease. These results show that mRNA expression for the functional components of dopaminergic neurotransmission is present in human cerebellum. The discrete changes in the levels of dopamine D1 and D3 receptors and tyrosine hydroxylase mRNA in cerebellum from l-DOPA treated Parkinson's disease patients suggests that this brain area has a role in the symptoms of Parkinson's disease and/or the beneficial/side-effects of treatment.
Aged, Aged, 80 and over, Antiparkinson Agents, Autopsy, Biomarkers, Case-Control Studies, Cerebellum, Dopamine Agents, Dopamine Plasma Membrane Transport Proteins, Female, Humans, Levodopa, Male, Membrane Glycoproteins, Membrane Transport Proteins, Nerve Tissue Proteins, Parkinson Disease, RNA, Messenger, Receptors, Dopamine, Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, Dopamine D3, Reverse Transcriptase Polymerase Chain Reaction, Substantia Nigra, Tyrosine 3-Monooxygenase, Journal Article, Research Support, Non-U.S. Gov't
2668-72
Hurley, Michael J
07b0180f-8e32-4ce1-8185-e046a42ef15a
Mash, Deborah C
8306c19c-264c-4b75-b534-39a039208779
Jenner, Peter
785c25df-ec64-4181-b057-26dd31cd9d84
27 October 2003
Hurley, Michael J
07b0180f-8e32-4ce1-8185-e046a42ef15a
Mash, Deborah C
8306c19c-264c-4b75-b534-39a039208779
Jenner, Peter
785c25df-ec64-4181-b057-26dd31cd9d84
Hurley, Michael J, Mash, Deborah C and Jenner, Peter
(2003)
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
European Journal of Neuroscience, 18 (9), .
(doi:10.1046/j.1460-9568.2003.02963.x).
Abstract
The presence of neuronal elements that are indicative of dopaminergic neurotransmission in cerebellum suggest that this brain region may contribute to the motor symptoms or dyskinesia seen in Parkinson's disease. Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of markers for dopaminergic neurotransmission in the cerebellum from postmortem brain tissue obtained from normal subjects and patients dying with Parkinson's disease who were receiving treatment with dopaminergic drugs. Dopamine D1-3 receptors, tyrosine hydroxylase and dopamine transporter mRNA was detected in the uvula and nodulus (lobules 9 and 10, respectively) of the vermis of cerebellum from normal individuals. In Parkinson's disease, the level of dopamine D1 and D3 receptor mRNA was significantly reduced in lobule 9 and the level of tyrosine hydroxylase mRNA was significantly reduced in lobule 10. No alteration in the level of dopamine D2 receptor or dopamine transporter mRNA was found in either lobule in patients with Parkinson's disease. These results show that mRNA expression for the functional components of dopaminergic neurotransmission is present in human cerebellum. The discrete changes in the levels of dopamine D1 and D3 receptors and tyrosine hydroxylase mRNA in cerebellum from l-DOPA treated Parkinson's disease patients suggests that this brain area has a role in the symptoms of Parkinson's disease and/or the beneficial/side-effects of treatment.
This record has no associated files available for download.
More information
Published date: 27 October 2003
Keywords:
Aged, Aged, 80 and over, Antiparkinson Agents, Autopsy, Biomarkers, Case-Control Studies, Cerebellum, Dopamine Agents, Dopamine Plasma Membrane Transport Proteins, Female, Humans, Levodopa, Male, Membrane Glycoproteins, Membrane Transport Proteins, Nerve Tissue Proteins, Parkinson Disease, RNA, Messenger, Receptors, Dopamine, Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, Dopamine D3, Reverse Transcriptase Polymerase Chain Reaction, Substantia Nigra, Tyrosine 3-Monooxygenase, Journal Article, Research Support, Non-U.S. Gov't
Identifiers
Local EPrints ID: 417222
URI: http://eprints.soton.ac.uk/id/eprint/417222
ISSN: 0953-816X
PURE UUID: 873456fb-0761-42d5-88ea-226bc4fb9748
Catalogue record
Date deposited: 25 Jan 2018 17:30
Last modified: 15 Mar 2024 17:13
Export record
Altmetrics
Contributors
Author:
Michael J Hurley
Author:
Deborah C Mash
Author:
Peter Jenner
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics